B
Brittney K Mize
Publications - 5
Citations - 26
Brittney K Mize is an academic researcher. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 3, co-authored 5 publications receiving 26 citations.
Papers
More filters
Journal ArticleDOI
Discovery of Anticancer Agents of Diverse Natural Origin.
Leslie N. Aldrich,Joanna E. Burdette,Esperanza J. Carcache de Blanco,Christopher C. Coss,Alessandra S. Eustáquio,James R. Fuchs,A. Douglas Kinghorn,Amanda MacFarlane,Brittney K Mize,Nicholas H. Oberlies,Jimmy Orjala,Cedric J. Pearce,Mitch A. Phelps,L. Harinantenaina Rakotondraibe,Yulin Ren,Djaja D. Soejarto,Brent R. Stockwell,Jack C. Yalowich,Xiaoli Zhang +18 more
TL;DR: Research progress from mainly over the last five years is described for a multidisciplinary collaborative program project directed toward the discovery of potential anticancer agents from a broad range of taxonomically defined organisms.
Journal ArticleDOI
PHY34 inhibits autophagy through V-ATPase V0A2 subunit inhibition and CAS/CSE1L nuclear cargo trafficking in high grade serous ovarian cancer
Amrita Salvi,Alexandria N. Young,Andrew C. Huntsman,Melissa R Pergande,Melissa A. Korkmaz,Rathnayake A C Rathnayake,Brittney K Mize,A. Douglas Kinghorn,Xiaoli Zhang,Kiira Ratia,Markus Schirle,Jason R. Thomas,Scott M. Brittain,Claude Shelton,Leslie N. Aldrich,S. Cologna,James R. Fuchs,Joanna E. Burdette +17 more
TL;DR: In this article , a synthetic small molecule called PHY34 was developed to have potent in vitro and in vivo anticancer activity against high grade serous ovarian cancer (HGSOC) cells.
Journal ArticleDOI
PHY34 inhibits autophagy through V-ATPase V0A2 subunit inhibition and CAS/CSE1L nuclear cargo trafficking in high grade serous ovarian cancer
Amrita Salvi,Alexandria N. Young,Andrew C. Huntsman,Melissa R Pergande,Melissa A. Korkmaz,Rathnayake A C Rathnayake,Brittney K Mize,A. Douglas Kinghorn,Xiaoli Zhang,Kiira Ratia,Markus Schirle,Jason R. Thomas,Scott M. Brittain,Claude Shelton,Leslie N. Aldrich,S. Cologna,James R. Fuchs,Joanna E. Burdette +17 more
TL;DR: In this paper , a synthetic small molecule called PHY34 was developed to have potent in vitro and in vivo anticancer activity against high grade serous ovarian cancer (HGSOC) cells.
Journal ArticleDOI
Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation.
Robert J. Tokarski,Chi Sharpe,Andrew C. Huntsman,Brittney K Mize,Oluwatosin R. Ayinde,Emily Stahl,James R Lerma,Andrew J. Rees,Bridget Carmichael,Natarajan Muthusamy,John C. Byrd,James R. Fuchs +11 more
TL;DR: In this paper , a series of protein degraders was developed, employing the clinically tested CDK inhibitor AT7519, and two distinct homologous series, a fully alkyl series and an amide-containing series, were prepared, demonstrating the dependence of degrader potency in these series on linker length.
Journal ArticleDOI
Discovery and development of botanical natural products and their analogues as therapeutics for ovarian cancer.
TL;DR: The taxane and camptothecin families represent significant therapeutics currently available for the treatment of ovarian cancer, and new drugs that have alternative mechanisms of action are still needed to combat the disease as mentioned in this paper .